Acumen Pharmaceuticals Inc（ABOS）资讯与事件ABOSAcumen Pharmaceuticals Inc

Acumen CEO Excited About Sabirnetug as Potential Early Alzheimer's Treatment

"This quarter we have been laser-focused on the readout preparations for our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, with topline results expected later this year. We are excited about the potential for sabirnetug to emerge as a potential treatment of choice with a differentiated benefit-to-risk profile given its unique product attributes as an anti-AbetaO, IgG2 monoclonal," said Daniel O'Connell, Chief Executive Officer of Acumen. "In the second quarter, we also announced the nomination of two Enhanced Brain Delivery candidates for the treatment of Alzheimer's Disease, representing the only program combining a validated blood-brain barrier-penetrating technology with an AbetaO-selective therapeutic antibody. We continue to advance IND-enabling activities toward a mid-2027 IND submission for a lead candidate, and are excited about the optionality this innovative product approach adds to our pipeline and the potential it holds to deliver a next-generation treatment for AD."

Acumen and JCR Showcase New Alzheimer's Findings

Acumen announced new findings presented at the Alzheimer's Association International Conference 2026 in London. Following collaboration with JCR Pharmaceuticals on EBD candidate development, studies demonstrated improved brain penetration of anti-AssO antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners. To evaluate transferrin receptor-mediated brain delivery, Acumen and JCR developed and characterized anti-AssO antibody fusion proteins incorporating J-Brain Cargo, JCR's clinically validated platform targeting the TfR, to facilitate brain uptake in humanized TfR mice. Fusion with anti-TfR fragments did not alter AssO affinity or selectivity. All EBD constructs achieved substantially higher brain levels than native anti-AssO antibodies, with each construct displaying a unique pharmacokinetic profile. Systemic absorption was confirmed after subcutaneous dosing and constructs retained the ability to bind Ass species of interest in human AD brain tissue. These findings support the continued advancement of lead EBD candidates and efforts to advance a construct to clinical trials. In collaboration with JCR, Acumen evaluated three bispecific antibodies fusing anti-AbetaO antibody with anti-TfR antibody fragments in cynomolgus monkeys. After intravenous dosing, all three bispecific antibodies achieved greater brain exposure than ACU234 alone, with at least 14-fold higher levels in the frontal cortex. Candidate molecule ACU401 demonstrated particularly robust brain penetration: 22-fold higher at 3 hours and 40-fold higher at 24 hours in the frontal cortex, with similar trends observed in the hippocampus and putamen. No hematological findings suggestive of anemia were observed. These results, together with evidence of systemic absorption after subcutaneous dosing, highlight the potential of EBD molecules for further development in early AD. Semi-structured interviews were conducted with 38 participants and their study partners prior to treatment in the ALTITUDE-AD Phase 2 study. Participants described pervasive memory-related challenges including forgetfulness, difficulty completing tasks, and communication difficulties. Emotional impacts, frustration, worry, and reduced confidence contributed to social withdrawal and reduced activity participation. Participants also reported actively managing others' perceptions of their symptoms through masking and selective disclosure. Together, results illustrate the diverse ways individuals with early Alzheimer's disease experience, respond to, and cope with cognitive and functional changes, underscoring the importance of capturing patient experience directly to better understand meaningful benefit at this stage of disease.

JCR Pharmaceuticals Partners with Acumen for Alzheimer's Treatment, Potential Revenue Up to $555 Million

JCR Pharmaceuticals (JCRRF) announced that Acumen Pharmaceuticals (ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease, enabled by JCR's proprietary blood-brain barrier-penetrating technology platform, J-Brain Cargo. The partnership, announced in July 2025, focuses on developing a BBB-penetrating treatment for AD that combines JCR's J-Brain Cargo with Acumen's amyloid beta oligomer-selective antibodies, which target toxic soluble AbetaOs, a key pathological driver in the onset and progression of AD. The collaborative program aims to demonstrate the feasibility of applying J-Brain Cargo in delivering sabirnetug, Acumen's targeted immunotherapy drug candidate, and other AbetaO-selective antibodies across the BBB to slow the progression of AD pathology. Earlier this year, Acumen presented non-clinical data from a mouse model of AD at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, which demonstrated that using AbetaO-selective antibodies with J-Brain Cargo technology increased brain exposure while preserving target engagement as demonstrated by AbetaO selectivity. Acumen plans to file an investigational new drug application for this program in mid-2027. Under the terms of the agreement, JCR will receive an option payment with Acumen's decision to exercise its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates from the collaboration. JCR will also be eligible to receive future milestone payments of up to $40M related to development, and up to $515M related to sales, for a total of up to $555M. In addition, JCR is entitled to receive tiered royalties based on net sales for any products that emerge from the collaboration.